Novamind Launches Palliative Program, Obtains DEA Licenses

Novamind, a mental health company that specializes in psychedelic medicine, recently announced the launch of the Psychedelic Palliative Care by Novamind program at its clinic and research site in Murray, Utah. The program combines psychedelic medicine with psychotherapy, workshops, immersive retreats, and group support for palliative care patients and families who are coping with chronic and serious illness.

Through its clinical research division, Novamind’s Palliative Program will host studies on the use of psychedelic medicine, including ketamine, and establish an infrastructure for future studies around the use of psilocybin.

The program is led by Novamind chief scientific officer Paul Thielking, MD, who has previously developed ketamine-assisted treatment protocols for cancer patients experiencing depression at the University of Utah Huntsman Cancer Institute.

Novamind also announced on Wednesday that it has been granted Schedule I licenses for psilocybin research from the US Drug Enforcement Agency for Thielking and chief medical officer Reid Robison, MD, MBA. The licenses are a requirement for sites planning to host psilocybin clinical trials because they allow principal investigators to store and administer the controlled substance.